Minomic
Minomic develops non-invasive blood tests for cancer. Its flagship product MiCheck uses a monclonal antibody to enable detection of a specific cancer-associated protein called Glypican-1. The company claims that the test is more sensitive and accurate than the gold standard prostate-specific antigen tests. The company was founded in 2000 and headquartered in Sydney, Australia. It has raised $8.1M in series a…
Funding snapshot
About
Minomic develops non-invasive blood tests for cancer. Its flagship product MiCheck uses a monclonal antibody to enable detection of a specific cancer-associated protein called Glypican-1. The company claims that the test is more sensitive and accurate than the gold standard prostate-specific antigen tests. The company was founded in 2000 and headquartered in Sydney, Australia. It has raised $8.1M in series a funding, with backing from ARC, NuSep, M.H. Carnegie & Co. The company operates in the Life Sciences - Oncology, Life Sciences - Genomics space. Non-invasive blood tests for cancer. Its offerings span Oncology - In-Vitro Diagnostic Tests - Prostate Cancer.
Business model
Oncology > In-Vitro Diagnostic Tests > Prostate Cancer,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.